Iowa is currently home to 799 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Iowa City, Des Moines, Sioux City and West Des Moines. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
Recruiting
The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Crohn's Disease
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Recruiting
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/30/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Sepsis, Acute Infection, Organ Failure
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Spinal Muscular Atrophy (SMA)
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #62, Des Moines, Iowa
Conditions: Head and Neck Squamous Cell Carcinoma
Implementing Group Battlefield Acupuncture in CCRCs for the Treatment of Chronic Lower Back Pain
Recruiting
Lower back pain (LBP) is one of the most common causes of disability, with 68% of adults over 60 years of age suffering from chronic Lower Back Pain (cLBP). In addition to the exacerbation of physical, social and emotional health issues, LBP has a staggeringly high US economic burden. Community-dwelling older adults experience a significant amount of chronic pain and treatments that are effective in their younger adult counterparts (e.g., pain medications, exercise) are often not safe or feasibl... Read More
Gender:
ALL
Ages:
Between 18 years and 115 years
Trial Updated:
01/28/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Pain, Back
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Recruiting
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/28/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Tumor Carcinoid, Carcinoid Tumor of GI System, Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Small-cell Lung Cancer
A Study of DF6002 Alone and in Combination With Nivolumab
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Solid Tumors
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Urothelial Carcinoma, Bladder Cancer
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 0061, Des Moines, Iowa
Conditions: Multiple Myeloma
Daily Aspirin Treatment After Preeclampsia
Recruiting
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lastin... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
01/27/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Preeclampsia
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Recruiting
This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior PD-1/PD-L1 checkpoint inhibitor therapy. The trial includes six cohorts: Cohorts 1-4: Patients who progressed after an initial response (PR or CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment) Cohort 5: Patients who progres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: University of Iowa Holden Comprehensive Cancer Center, Iowa City, Iowa
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
Recruiting
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Investigational Site (219), Iowa City, Iowa
Conditions: Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease